cagrisema cagrilintide semaglutide phase 3 obesity Novo Nordisk has officially filed for FDA approval of CagriSema, a powerful new once-weekly injection that combines a GLP-1 receptor agonist with an amylin analogue, setting the stage for the next major CagriSema vs Retatrutide: Amylin/GLP-1 Combination

Researchers have studied 5-Amino-1MQ in the context of diet-induced obesity models and cellular metabolic flux

For another key nutrient in this space, see our guide on magnesium for anxiety and stress, which covers the GABA and parasympathetic pathways that complement what B12 does on the neurotransmitter side

Thymosin Alpha-1 and Thymosin Beta-4 are great for restoring the immune system and reducing inflammation

Upregulation of Growth Factors BPC-157 enhances the expression of several key growth factors, including: VEGF (vascular endothelial growth factor) TGF- (transforming growth factor beta) FGF (fibroblast growth factor) EGF (epidermal growth factor) These factors collectively support cellular proliferation, matrix remodeling, and tissue regeneration

Pentadecapeptide BPC 157 and anaphylactoid reaction in rats and mice after intravenous dextran and white egg administration

In its initial studies, Novo Nordisk found that cagrilintide led to more weight loss and better muscle preservation than semaglutide